Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Horizon Therapeutics (HZNP)

Horizon Therapeutics (HZNP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,256,901
  • Shares Outstanding, K 186,448
  • Annual Sales, $ 1,208 M
  • Annual Income, $ -74,190 K
  • 60-Month Beta 0.83
  • Price/Sales 4.21
  • Price/Cash Flow 6.89
  • Price/Book 3.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 0.51
  • Number of Estimates 4
  • High Estimate 0.51
  • Low Estimate 0.50
  • Prior Year 0.65
  • Growth Rate Est. (year over year) -21.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.03 +14.24%
on 10/02/19
28.76 -0.56%
on 10/16/19
+2.59 (+9.96%)
since 09/16/19
3-Month
22.84 +25.22%
on 08/05/19
28.76 -0.56%
on 10/16/19
+4.76 (+19.97%)
since 07/16/19
52-Week
16.56 +72.71%
on 10/26/18
29.44 -2.85%
on 02/28/19
+9.38 (+48.80%)
since 10/16/18

Most Recent Stories

More News
Shares of Horizon Pharma P Rank the Highest in Terms of Relative Performance in the Pharmaceuticals Industry (HZNP , MRK , MDCO , PFE , BMY )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

HZNP : 28.60 (+1.44%)
MDCO : 54.59 (+2.84%)
MRK : 84.45 (-0.69%)
New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People with Active Thyroid Eye Disease

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data from the Phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several devastating effects...

HZNP : 28.60 (+1.44%)
For World Sight Day, Horizon and Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put "Vision First"

Today, in support of World Sight Day, Horizon Therapeutics plc (Nasdaq: HZNP) and Prevent Blindness launched a campaign that brings together the voices of the thyroid eye disease (TED) community to educate...

HZNP : 28.60 (+1.44%)
Horizon Therapeutics plc to Release Third-Quarter 2019 Financial Results and Host Webcast on Nov. 6, 2019

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its third-quarter 2019 financial results will be released on Wednesday, Nov. 6, 2019. Following the announcement, Horizon's management will...

HZNP : 28.60 (+1.44%)
New Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium

Additional results from the Phase 3 confirmatory clinical trial (OPTIC) of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc, will be presented at the American Society...

HZNP : 28.60 (+1.44%)
Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named one of the top 100 adoption-friendly workplaces in the country by the Dave Thomas Foundation for Adoption, ranking number...

HZNP : 28.60 (+1.44%)
Horizon Pharma P Shares Up 26.0% Since SmarTrend's Buy Recommendation (HZNP)

SmarTrend identified an Uptrend for Horizon Pharma P (NASDAQ:HZNP) on January 7th, 2019 at $20.83. In approximately 9 months, Horizon Pharma P has returned 26.00% as of today's recent price of $26.24....

HZNP : 28.60 (+1.44%)
Pacira Pharmaceu has the Best Relative Performance in the Pharmaceuticals Industry (PCRX , SUPN , HZNP , ZTS , JNJ )

Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have...

HZNP : 28.60 (+1.44%)
PCRX : 39.03 (+2.44%)
SUPN : 26.18 (-0.11%)
32.1% Return Seen to Date on SmarTrend Horizon Pharma P Call (HZNP)

SmarTrend identified an Uptrend for Horizon Pharma P (NASDAQ:HZNP) on January 7th, 2019 at $20.83. In approximately 9 months, Horizon Pharma P has returned 32.10% as of today's recent price of $27.51....

HZNP : 28.60 (+1.44%)
Look for Shares of Horizon Pharma P to Potentially Pullback after Yesterday's 1.14% Rise

Horizon Pharma P (NASDAQ:HZNP) traded in a range yesterday that spanned from a low of $27.08 to a high of $27.72. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high...

HZNP : 28.60 (+1.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade HZNP with:

Business Summary

Horizon Therapeutics PLC is a biopharmaceutical company. It is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines which address unmet medical needs. The Company markets medicines through its orphan, rheumatology and primary care business units. ...

See More

Key Turning Points

2nd Resistance Point 29.30
1st Resistance Point 28.95
Last Price 28.60
1st Support Level 28.06
2nd Support Level 27.52

See More

52-Week High 29.44
Last Price 28.60
Fibonacci 61.8% 24.52
Fibonacci 50% 23.00
Fibonacci 38.2% 21.48
52-Week Low 16.56

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar